Topical beremagene geperpavec + Placebo gel
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dystrophic Epidermolysis Bullosa
Conditions
Dystrophic Epidermolysis Bullosa
Trial Timeline
May 6, 2018 → Nov 1, 2019
NCT ID
NCT03536143About Topical beremagene geperpavec + Placebo gel
Topical beremagene geperpavec + Placebo gel is a phase 1/2 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT03536143. Target conditions include Dystrophic Epidermolysis Bullosa.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03536143 | Phase 1/2 | Completed |
Competing Products
4 competing products in Dystrophic Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KB803 + Placebo | Krystal Biotech | Phase 3 | 74 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 74 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 74 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 33 |